Secondary acute myelogenous leukemia following safe exposure to etoposide

被引:51
作者
Stine, KC [1 ]
Saylors, RL [1 ]
Sawyer, JR [1 ]
Becton, DL [1 ]
机构
[1] UNIV ARKANSAS MED SCI HOSP,ARKANSAS CHILDRENS HOSP,DEPT PATHOL,LITTLE ROCK,AR 72202
关键词
D O I
10.1200/JCO.1997.15.4.1583
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To present two patients as illustrations of the risk of developing secondary acute myelogenous leukemia (sAML) when theoretically safe doses of etoposide (VP-16) ore used. Patients and Methods: Patient no, 1 was a 15-year-old white girl diagnosed with stage IIa Hodgkin's disease. She was treated with a combination of vincristine, doxorubicin, bleomycin, and VP-16 (2 g/m(2) total) over 4 months, followed by 25.5 Gy of involved-field radiotherapy. Patient no. 2 was an 11-year-old white boy diagnosed with virus-associated hemophagocytic syndrome (VAHS). He was treated with VP-16 intravenously (IV) and orally (0.3 g and 2.8 g/m(2), respectively). Results: Patient no. 1 developed AML 16 months from the diagnosis of Hodgkin's disease. Patient no. 2 developed AML 26 months from diagnosis. Both bone marrows were consistent with French-American-British (FAB) M4 disease. Both patients had abnormalities of the long arm of chromosome 11. Conclusion: The use of low-dose or oral VP-16 can be associated with the development of sAML. Clinicians should be cautious in the use of VP-16 in low-risk diseases. (C) 1997 by American Society of Clinical Oncology.
引用
收藏
页码:1583 / 1586
页数:4
相关论文
共 16 条
[1]   ACUTE NONLYMPHOCYTIC LEUKEMIA IN GERM-CELL TUMOR PATIENTS TREATED WITH ETOPOSIDE-CONTAINING CHEMOTHERAPY [J].
BAJORIN, DF ;
MOTZER, RJ ;
RODRIGUEZ, E ;
MURPHY, B ;
BOSL, GJ .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (01) :60-62
[2]   ACUTE-LEUKEMIA AFTER THE TREATMENT OF HODGKIN DISEASE [J].
HENRYAMAR, M ;
DIETRICH, PY .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1993, 7 (02) :369-387
[3]   PHARMACODYNAMICS AND LONG-TERM TOXICITY OF ETOPOSIDE [J].
KOBAYASHI, K ;
RATAIN, MJ .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1994, 34 :S64-S68
[4]   LCH-I - A RANDOMIZED TRIAL OF ETOPOSIDE VS VINBLASTINE IN DISSEMINATED LANGERHANS CELL HISTIOCYTOSIS [J].
LADISCH, S ;
GADNER, H ;
ARICO, M ;
BROADBENT, V ;
GROIS, N ;
JACOBSON, A ;
KOMP, D ;
NICHOLSON, HS .
MEDICAL AND PEDIATRIC ONCOLOGY, 1994, 23 (02) :107-110
[5]  
Ladisch S, 1994, BR J CANC S, V23, pS41
[6]  
LEVENTHAL BG, 1989, PRINCIPLES PRACTICE, P457
[7]   SECONDARY LEUKEMIA ASSOCIATED WITH A CONVENTIONAL DOSE OF ETOPOSIDE - REVIEW OF SERIAL GERM-CELL TUMOR PROTOCOLS [J].
NICHOLS, CR ;
BREEDEN, ES ;
LOEHRER, PJ ;
WILLIAMS, SD ;
EINHORN, LH .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (01) :36-40
[8]  
NICHOLS CR, 1992, SEMIN ONCOL, V19, P72
[9]  
PUI CH, 1995, LEUKEMIA, V9, P1680
[10]   SECONDARY ACUTE MYELOID-LEUKEMIA IN CHILDREN TREATED FOR ACUTE LYMPHOID LEUKEMIA [J].
PUI, CH ;
BEHM, FG ;
RAIMONDI, SC ;
DODGE, RK ;
GEORGE, SL ;
RIVERA, GK ;
MIRRO, J ;
KALWINSKY, DK ;
DAHL, GV ;
MURPHY, SB ;
CRIST, WM ;
WILLIAMS, DL .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (03) :136-142